Janus Kinase 1

• 

  Subject Areas on Research

  • 27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6-JAK-STAT3 Signaling in Prostate Cancer Cells. 
  • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. 
  • ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. 
  • Associations of potentially functional variants in IL-6, JAKs and STAT3 with gastric cancer risk in an eastern Chinese population. 
  • Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor. 
  • Genome-Wide Association Meta-Analysis Reveals Novel Juvenile Idiopathic Arthritis Susceptibility Loci. 
  • Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. 
  • Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. 
  • Janus kinase inhibitors for atopic dermatitis: a promising treatment modality. 
  • Mammalian and Drosophila blood: JAK of all trades? 
  • MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. 
  • Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. 
  • Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. 
  • SOCS1, SOCS3, and PIAS1 promote myogenic differentiation by inhibiting the leukemia inhibitory factor-induced JAK1/STAT1/STAT3 pathway. 
  • The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors. 
  • Translational profiling of cardiomyocytes identifies an early Jak1/Stat3 injury response required for zebrafish heart regeneration. 
  • Untangle a Broken Heart via Janus Kinase 1. 
  • miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma.